NanoLogix >1-Hour Covid-19 Detection Test Now

NanoLogix >1-Hour Covid-19 Detection Test Now

Patent-Pending

Patent Application Filed Under New COVID-19 Prioritized Examination Pilot Program









NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.



This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.

While the initial focus for development was for the COVID-19 virus, it became obvious that the technology

is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".





An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.



Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19."





The US Patent Office program under which the filing was done can be accessed through the following link:



https://www.federalregister.gov/documents/202...program​

---